Impact of Metformin on Cardiovascular and Kidney Outcomes in Type 2 Diabetic Patients

Metformin for type 2 diabetes mellitus (T2DM) patients is linked to a decreased risk of experiencing severe diabetic nephropathy and major cardiovascular events. 

For T2DM patients with compromised kidney functions, maintaining metformin therapy is connected to reduced risk of major kidney and cardiovascular events compared with non-metformin user or discontinued user. 

Metformin usage among T2DM patients, regardless of their renal functions variation, consistently shows a lower risk of severe diabetic nephropathy (DN), major adverse cardiovascular events (MACE), and major adverse kidney events (MAKE) compared with the control cohort. 

 

 

 

Reference:
Yongjin Yi, et al. Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study. Sci Rep 14, 2081 (2024).